Cuproptosis predicts the risk and clinical outcomes of lung adenocarcinoma

Hu, Qin; Wang, Runtian; Ma, Huiyun; Zhang, Zhouwei; Xue, Qun

doi:10.3389/fonc.2022.922332

Cited by 32 publications

(21 citation statements)

References 50 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical information was gathered, including TNM stage, pathological grade, age, gender, follow-up period, and survival status. In this study, 22 genes associated with cuproptosis were chosen for examination based on previously published studies [ 7 , 12 , 13 , 14 ].…”

Section: Methodsmentioning

confidence: 99%

Cuproptosis-Related lncRNA Gene Signature Establishes a Prognostic Model of Gastric Adenocarcinoma and Evaluate the Effect of Antineoplastic Drugs

Zhang

Xue

et al. 2022

Genes

View full text Add to dashboard Cite

Background: One of the most frequent malignancies of the digestive system is stomach adenocarcinoma (STAD). Recent research has demonstrated how cuproptosis (copper-dependent cell death) differs from other cell death mechanisms that were previously understood. Cuproptosis regulation in tumor cells could be a brand-new treatment strategy. Our goal was to create a cuproptosis-related lncRNA signature. Additionally, in order to evaluate the possible immunotherapeutic advantages and drug sensitivity, we attempted to study the association between these lncRNAs and the tumor immune microenvironment of STAD tumors. Methods: The TCGA database was accessed to download the RNA sequencing data, genetic mutations, and clinical profiles for TCGA STAD. To locate lncRNAs related to cuproptosis and build risk-prognosis models, three techniques were used: co-expression network analysis, Cox-regression techniques, and LASSO techniques. Additionally, an integrated methodology was used to validate the models’ predictive capabilities. Then, using GO and KEGG analysis, we discovered the variations in biological functions between each group. The link between the risk score and various medications for STAD treatment was estimated using the tumor mutational load (TMB) and tumor immune dysfunction and rejection (TIDE) scores. Result: We gathered 22 genes linked to cuproptosis based on the prior literature. Six lncRNAs related to cuproptosis were used to create a prognostic marker (AC016394.2, AC023511.1, AC147067.2, AL590705.3, HAGLR, and LINC01094). After that, the patients were split into high-risk and low-risk groups. A statistically significant difference in overall survival between the two groups was visible in the survival curves. The risk score was demonstrated to be an independent factor affecting the prognosis by both univariate and multivariate Cox regression analysis. Different risk scores were substantially related to the various immunological states of STAD patients, as further evidenced by immune cell infiltration and ssGSEA analysis. The two groups had differing burdens of tumor mutations. In addition, immunotherapy was more effective for STAD patients in the high-risk group than in the low-risk group, and risk scores for STAD were substantially connected with medication sensitivity. Conclusions: We discovered a marker for six cuproptosis-associated lncRNAs linked to STAD as prognostic predictors, which may be useful biomarkers for risk stratification, evaluation of possible immunotherapy, and assessment of treatment sensitivity for STAD.

show abstract

Section: Methodsmentioning

confidence: 99%

Cuproptosis-Related lncRNA Gene Signature Establishes a Prognostic Model of Gastric Adenocarcinoma and Evaluate the Effect of Antineoplastic Drugs

Zhang

Xue

et al. 2022

Genes

View full text Add to dashboard Cite

show abstract

“…Cuproptosis-linked genes perform an essential role in tumor occurrence and progression. Researchers conducted in-depth research on bladder cancer [41], clear cell renal cell carcinoma [42], hepatocellular carcinoma [43], lung adenocarcinoma [44], and other diseases. However, until now, no research has been conducted to analyze cuproptosis-linked genes in patients with pRCC.…”

Section: Discussionmentioning

confidence: 99%

A cuproptosis-related long non-coding RNA risk coefficient model to predict outcomes and therapeutic responses in papillary renal cell carcinoma

Tang

Yang

Huang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Papillary renal cell carcinoma (pRCC) is the second most common subtype of renal cell carcinoma, second only to clear cell renal cell carcinoma (ccRCC). Compared with ccRCC, metastatic pRCC has worse outcomes. Copper is an essential micronutrient; its accumulation is related to cancer proliferation, growth, angiogenesis, and metastasis. The abnormal expression of long non-coding RNA (lncRNA) plays an essential role in developing pRCC. Our study aimed to predict outcomes in pRCC patients using a prognostic risk coefficient model for cuproptosis-related lncRNAs. Methods We obtained data from pRCC patients and cuproptosis-related genes from The Cancer Genome Atlas and the literature. Cuproptosis-related lncRNAs were obtained using co-expression analysis based on R language software. The prognostic risk model of cuproptosis-related pRCC was established using univariate and multivariate Cox regressions and LASSO regression analysis, and the model was validated. The high- and low-risk groups were divided by the median value of the risk coefficient. Finally, we performed correlation analysis and potential drug identification for high- and low-risk subgroups. Results Seven cuproptosis-related lncRNAs were included (AC019080.5, AC092807.3, AC107464.2, AL5941845.1, GCC2-AS1, NINJ2-AS1, and ZNF710-AS1). Riskscore and tumor stage were independent prognostic factors in pRCC. Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway functional enrichment analysis showed that differentially expressed genes in pRCC cuproptosis-related lncRNAs were associated with the pathways of collagen-containing extracellular matrix formation and intracellular and extracellular structure formation. Correlation analysis of immune function showed that type II interferon responses, immune checkpoints, co-inhibition of T cells, cytolysis, co-inhibition of antigen-presenting cells, and human leukocyte antigen were significantly different between high- and low-risk groups. Higher Tumor Immune Dysfunction and Exclusion scores were observed in the low-risk group in the immune escape association analysis, illustrating the suboptimal effect of immunotherapy in low-risk patients. We identified 5-fluorouracil, epothilone B, gemcitabine, paclitaxel, pazopanib, and sunitinib as potentially more beneficial in the high-risk group; bortezomib, erlotinib, and sorafenib were more beneficial in the low-risk group. Conclusion We identified seven cuproptosis-related lncRNAs associated with pRCC outcomes and constructed a prognostic model that provides a basis for basic research and pRCC precision treatment.

show abstract

Section: Data Collectionmentioning

confidence: 99%

Coproptosis related lncRNAs gene signature establishes a prognostic model of gastric adenocarcinoma and evaluate the effect of antineoplastic drugs

Zhang

Xue

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: One of the most frequent malignancies of the digestive system is stomach adenocarcinoma (STAD). Recent research has demonstrated how Cuproptosis (copper-dependent cell death) differs from other cell death mechanisms that were previously understood. Cuproptosis regulation in tumour cells could be a brand-new treatment strategy. Our goal was to create a cuproptosis-related lncRNAs signature. Additionally, in order to evaluate the possible immunotherapeutic advantages and drug sensitivity, we attempted to study the association between these lncRNAs and the tumour immune microenvironment of STAD tumours. The TCGA database was accessed to download the RNA sequencing data, genetic mutations, and clinical profiles for TCGA STAD. To locate lncRNAs related with cuproptosis and build risk-prognosis models, three techniques were used: co-expression network analysis, Cox-regression techniques, and LASSO techniques. Additionally, an integrated methodology was used to validate the models' predictive capabilities. Then, using GO and KEGG analysis, we discovered the variations in biological functions between each group. The link between the risk score and various medications for STAD treatment was estimated using the tumour mutational load (TMB) and tumour immune dysfunction and rejection (TIDE) scores. Result: We gathered 22 genes linked to cuproptosis based on prior literature. Six lncRNAs related with cuproptosis were used to create a prognostic marker (AC016394.2, AC023511.1, AC147067.2, AL590705.3, HAGLR, and LINC01094). After that, the patients were split into high-risk and low-risk groups. A statistically significant difference in overall survival between two groups was visible in the survival curves. The risk score was demonstrated to be an independent factor affecting the prognosis by both univariate and multivariate Cox regression analysis. Different risk scores were substantially related with the various immunological states of STAD patients, as further evidenced by immune cell infiltration and ssGSEA analysis. The two groups had differing burdens of tumour mutations. In addition, immunotherapy was more effective for STAD patients in the high-risk group than in the low-risk group, and risk scores for STAD were substantially connected with medication sensitivity. Conclusions: We discovered a marker for 6-cuproposis-associated lncRNAs linked to STAD as prognostic predictors, which may be useful biomarkers for risk stratification, evaluation of possible immunotherapy, and assessment of treatment sensitivity for STAD.

show abstract

Cuproptosis predicts the risk and clinical outcomes of lung adenocarcinoma

Cited by 32 publications

References 50 publications

Cuproptosis-Related lncRNA Gene Signature Establishes a Prognostic Model of Gastric Adenocarcinoma and Evaluate the Effect of Antineoplastic Drugs

Cuproptosis-Related lncRNA Gene Signature Establishes a Prognostic Model of Gastric Adenocarcinoma and Evaluate the Effect of Antineoplastic Drugs

A cuproptosis-related long non-coding RNA risk coefficient model to predict outcomes and therapeutic responses in papillary renal cell carcinoma

Coproptosis related lncRNAs gene signature establishes a prognostic model of gastric adenocarcinoma and evaluate the effect of antineoplastic drugs

Contact Info

Product

Resources

About